Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025
Rhea-AI Summary
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its Q2 2025 financial results announcement for August 12, 2025.
The company will release results before market open, followed by a management-hosted webcast conference call at 8:30 a.m. ET on the same day. The webcast will be available on the company's website and archived for future reference.
Positive
- None.
Negative
- None.
News Market Reaction 8 Alerts
On the day this news was published, RPID declined 0.60%, reflecting a mild negative market reaction. Argus tracked a peak move of +9.7% during that session. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $941K from the company's valuation, bringing the market cap to $156M at that time.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) release Q2 2025 earnings?
What time is the RPID Q2 2025 earnings conference call?
How can investors access Rapid Micro Biosystems Q2 2025 earnings call?
What does Rapid Micro Biosystems (RPID) do?
